[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524352":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":19,"locations":20,"responsibleParty":40,"collaborators":19,"id":42,"slug":19,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":19,"enrollmentInfo":50,"targetDuration":19,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":23,"whyStopped":19,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Jules Bordet Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"FAPI PET\u002FCT","EXPERIMENTAL","The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is injected intravenously for molecular imaging of FAP expression with FAPI PET\u002FCT in patients with NSCLC with an indication for immunotherapy",[13],"Procedure: FAPI PET\u002FCT",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is injected intravenously for molecular imaging of FAP expression with FAPI PET\u002FCT.",[9],null,[21],{"facility":22,"status":23,"city":24,"state":19,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Institut Jules Bordet","RECRUITING","Brussels","1070","Belgium","BE",{"type":29,"coordinates":30},"Point",[31,32],4.34878,50.85045,{"lat":32,"lon":31},[35],{"name":36,"role":37,"phone":38,"phoneExt":19,"email":39},"Loubna Taraji Schiltz","CONTACT","+32 (0) 2 541 37 81","loubna.taraji@hubruxelles.be",{"type":41,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100524352",false,"NCT06107608","Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors","LIFE","Inclusion Criteria:\n\n* Age above 18 years.\n* Pathologically- proven non-small-cell lung cancer (NSCLC).\n* Proposed for treatment with anti-PD-(L)1 alone or in combination with chemotherapy and\u002For anti-CTLA4 in the advanced setting.\n* ECOG Performance status ≤2.\n* Patient's written informed consent obtained prior to any study procedure.\n\nExclusion Criteria:\n\n* Surgery and\u002For radiotherapy to thoracic region within the last 8 weeks or anti-cancer systemic therapy within the last 2 weeks.\n* Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and c-ros oncogene (ROS1) mutations.\n* Pregnant and lactating women\n* Previous or concurrent malignancy diagnosed within the last 2 years except adequately treated in situ carcinoma of the cervix uteri, localised (T1N0) low grade (Gleason score 6) prostate cancer undergoing active surveillance and basal or squamous cell skin cancer.\n* Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.","ALL","18 Years",{"count":51,"type":52},58,"ESTIMATED","INTERVENTIONAL",[55],"NA","Evaluation of the relation between baseline fibroblast activation protein (FAP) expression based on Ga-FAPI uptake with patient outcome among NSCLC patients receiving immunotherapy for recurrent\u002Fmetastatic disease.",[58],"Non Small Cell Lung Cancer",[60,61,58,62,63,64,65],"Immunotherapy","FAPI-46","PET","PET\u002FCT","fibroblast activation protein","fibroblast activation protein inhibitor","2025-03-26",{"date":68,"type":69},"2025-03-31","ACTUAL",{"date":71,"type":69},"2023-06-13",{"date":73,"type":52},"2027-12-01",{"name":5,"class":6},1]